PMID- 26438035
OWN - NLM
STAT- MEDLINE
DCOM- 20160831
LR  - 20181113
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 15
DP  - 2015 Oct 5
TI  - Extracts from Aralia elata (Miq) Seem alleviate hepatosteatosis via improving 
      hepatic insulin sensitivity.
PG  - 347
LID - 10.1186/s12906-015-0871-5 [doi]
LID - 347
AB  - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease 
      that is strongly associated with obesity and dysregulation of insulin in the 
      liver. However, currently no pharmacological agents have been established for the 
      treatment of NAFLD. In this regard, we sought to evaluate the anti-NAFLD effects 
      of Aralia elata (Miq) Seem (AE) extract and its ability to inhibit hepatic lipid 
      accumulation and modulate cellular signaling in a high fat diet (HFD)-induced 
      obese mouse model. METHODS: A model of hepatic steatosis in the HepG2 cells was 
      induced by oleic acid. Intracellular lipid droplets were detected by Oil-Red-O 
      staining, and the expression of sterol regulatory element-binding protein 
      1(SREBP-1), Fatty acid synthase (FAS), Acetyl-CoA carboxylase (ACC) 1 and 2, 
      Peroxisome proliferator activated receptor-alpha (PPARalpha), and carnitine palmitoyl 
      transferase 1(CPT-1) was analyzed by real time reverse transcription-Polymerase 
      chain reaction (qRT-PCR). And glucose consumption was measured with commercial 
      kit. Furthermore, Male C57BL/6 J mice were fed with HFD to induce NAFLD. Groups 
      of mice were given plant extracts orally at 100 and 300 mg/kg at daily for 4 
      weeks. After 3 weeks of AE extract treatment, we performed oral glucose tolerance 
      test (OGTT). Liver tissue was procured for histological examination, 
      Phosphoinositide 3-kinase (PI3K) and Protein kinase B (PKB/Akt) activity. 
      RESULTS: In the present study, AE extract was shown to reduce hepatic lipid 
      accumulation and significantly downregulate the level of lipogenic genes and 
      upregulate the expression of lipolysis genes in HepG2 cells. And also, AE extract 
      significantly increased the glucose consumption, indicating that AE extract 
      improved insulin resistance. Subsequently, we confirmed the inhibitory activity 
      of AE extract on NAFLD, in vivo. Treatment with AE extract significantly 
      decreased body weight and the fasting glucose level, alleviated hyperinsulinism 
      and hyperlipidemia, and reduced glucose levels, as determined by OGTT. 
      Additionally, AE extract decreased PI3K and Akt activity. CONCLUSIONS: Our 
      results suggest that treatment with AE extract ameliorated NAFLD by inhibiting 
      insulin resistance through activation of the Akt/GLUT4 pathway.
FAU - Hwang, Kyung-A
AU  - Hwang KA
AD  - Department of Agrofood Resources, National Academy of Agricultural Science, RDA, 
      Wanju-Gun, Jeollabuk-do, 565-851, Republic of Korea. kah366@korea.kr.
FAU - Hwang, Yu-Jin
AU  - Hwang YJ
AD  - Department of Agrofood Resources, National Academy of Agricultural Science, RDA, 
      Wanju-Gun, Jeollabuk-do, 565-851, Republic of Korea. yjhwang1022@korea.kr.
FAU - Kim, Ga Ram
AU  - Kim GR
AD  - Department of Agrofood Resources, National Academy of Agricultural Science, RDA, 
      Wanju-Gun, Jeollabuk-do, 565-851, Republic of Korea. ysamang@skku.edu.
FAU - Choe, Jeong-Sook
AU  - Choe JS
AD  - Department of Agrofood Resources, National Academy of Agricultural Science, RDA, 
      Wanju-Gun, Jeollabuk-do, 565-851, Republic of Korea. swany@korea.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151005
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Insulin)
RN  - 0 (PPAR alpha)
RN  - 0 (Plant Extracts)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - EC 2.3.1.21 (Carnitine O-Palmitoyltransferase)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
SB  - IM
MH  - Animals
MH  - Aralia/*chemistry
MH  - Carnitine O-Palmitoyltransferase/genetics/metabolism
MH  - Diet, High-Fat/adverse effects
MH  - Humans
MH  - Insulin/*metabolism
MH  - Liver/drug effects/*metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/enzymology/genetics/metabolism
MH  - PPAR alpha/genetics/metabolism
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - Plant Extracts/*administration & dosage
MH  - Sterol Regulatory Element Binding Protein 1/genetics/metabolism
PMC - PMC4595215
EDAT- 2015/10/07 06:00
MHDA- 2016/09/01 06:00
PMCR- 2015/10/05
CRDT- 2015/10/07 06:00
PHST- 2015/06/09 00:00 [received]
PHST- 2015/09/21 00:00 [accepted]
PHST- 2015/10/07 06:00 [entrez]
PHST- 2015/10/07 06:00 [pubmed]
PHST- 2016/09/01 06:00 [medline]
PHST- 2015/10/05 00:00 [pmc-release]
AID - 10.1186/s12906-015-0871-5 [pii]
AID - 871 [pii]
AID - 10.1186/s12906-015-0871-5 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2015 Oct 5;15:347. doi: 10.1186/s12906-015-0871-5.